Navigation Links
Isis Pharmaceuticals to Discuss Its Neurodegenerative Franchise in a Conference Call on Thursday, June 17
Date:6/15/2010

CARLSBAD, Calif., June 15 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it will conduct the fourth and last of this series of conference calls focused on the drugs in Isis' development pipeline.  The last call of the series will focus on Isis' neurodegenerative franchise and will be held on Thursday, June 17, 2010 at 12:00 p.m. ET.  This call will be archived for a limited time on Isis' Web site.

Isis has conducted three earlier calls that highlighted its cardiovascular, metabolic and cancer franchises.  The last call of the series will focus on Isis' neurodegenerative franchise as well as some of the other promising programs Isis and its partners are developing.  

Conference Call

At 12:00 p.m. Eastern Time Thursday, June 17, 2010, Isis will conduct a live webcast conference call.  Interested parties may listen to the call by dialing 866-831-6247 and refer to passcode "ISIS 2010" or access the webcast at www.isispharm.com.  A webcast replay will be available for a limited time at the same address.  

Isis' Neurodegenerative Franchise

Isis is pursuing the discovery and development of antisense drugs for neurodegenerative diseases in which there is a large unmet need for new treatment options.  Isis' initial goal is to develop antisense drugs to treat severe diseases with identified genetic causes.  Isis has initiated several programs to develop drugs to treat severe neurodegenerative disease and funded three of these programs in part through grants.  The most advanced program in Isis' neurodegenerative franchise is its SOD1 drug to treat amyotrophic lateral sclerosis, or ALS, also known as Lou Gehrig's disease.  Isis recently added a drug designed to treat spinal muscular atrophy into its development pipeline and is developing novel treatments for other severe neurodegenerative diseases.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 22 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide.  Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding the development, activity, therapeutic potential and safety of the drugs in Isis' pipeline.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2009 and its most recent quarterly report on Form 10-Q, which are on file with the SEC.  Copies of these and other documents are available from the Company.  

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc.

Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics is a trademark of Regulus Therapeutics Inc.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... ... generally produce small, heterogeneous samples with limited tumor content in a large background ... be resolved, such as the need for reliable detection of low abundance somatic ...
(Date:3/27/2017)... Md. , March 27, 2017  The ... billion for 2016, according to a new report ... medical lab testing is performed to evaluate disease ... individual therapy, among other reasons.  The healthcare market ... Market , provides an overview of the ...
(Date:3/27/2017)... DUBLIN , March 27, 2017 ... access to a comprehensive library of reports on Valero ... the transportation fuels and petrochemical industries. ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO) ... is biofuel production to go green. Ethanol today, even though ...
(Date:3/27/2017)... ... March 27, 2017 , ... A research ... customizable vascular grafts in JoVE’s Video Journal, the world’s first peer-reviewed scientific video ... ways of treating coronary artery disease (CAD). Lam is an assistant professor at ...
Breaking Biology Technology:
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... to 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market ... the next decade to reach approximately $14.21 billion by 2025. ... for all the given segments on global as well as regional ...
Breaking Biology News(10 mins):